AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01683461 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Women in the standard of care arm receive HIV pre and post-test counseling at their first antenatal visit. The counseling provided to them adheres to international guidelines for HIV counseling and testing developed by US CDC and the World Health Organization.
Study NCT03882632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fat Grafting for Fecal Incontinence
Description: Autologous adiopse tissue harvesting/grafting using Lipogems
Study NCT03036267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BREATHE
Description: Primary care providers (PCPs) randomized to BREATHE will be trained to deliver the 7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach.
Study NCT03036267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Condition
Description: PCPs randomized to the control intervention will not receive any specific training. To control for contact, they will be instructed to engage in a 7-minute diet and exercise discussion as this will not confound results.
Study NCT01571843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forearm exercise program
Description: Participants assigned to forearm exercise will receive training in forearm strengthening exercises from a doctoral occupational therapy student. Participants will be taught 8 exercises and are performed at home. The exercise program is designed to take about 30 minutes per session.
Study NCT01571843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forearm exercise program
Description: Participants assigned to forearm exercise will receive training in forearm strengthening exercises from a doctoral occupational therapy student. Participants will be taught 8 exercises and are performed at home. The exercise program is designed to take about 30 minutes per session.
Study NCT01571843 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Walking program
Description: Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks. The walking program for all participants constitutes the control/placebo comparator.
Study NCT03847571 — intervention group
Intervention type: DRUG
Intervention: Acetazolamide
Description: Correction of metabolic alkalosis by inhibition of the filtered bicarbonate load reabsorption in the proximal tubules using acetazolamide (AZ)
Study NCT00641563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Infusion of dexmedetomidine
Study NCT00641563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam infusion
Study NCT00641563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Infusion of remifentanil
Study NCT00934375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept (donepezil hydrochloride)
Description: 5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.
Study NCT00934375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT05076734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Redraw for analysis of blood samples from healthy pregnant women
Description: If less than two fetal cells are recovered from maternal blood, a redraw is indicated
Study NCT01715051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-serine
Description: The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.
Study NCT01715051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).
Study NCT01715051 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).
Study NCT01715051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.
Study NCT02097732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.
Study NCT02097732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.
Study NCT02097732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.
Study NCT02097732 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.
Study NCT00913601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic INTERSIM II - 3058
Description: Medtronic INTERSIM II - 3058 Impuls Generator
Study NCT01654276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: One 40 mg tablet once a day for 6 months
Study NCT03720925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TDI treatment
Description: The TDI treatment was performed according to its complexity. Uncomplicated TDI received minimally invasive treatment (simple restorations and clinical and radiographic follow-up). Complicated TDI received invasive treatment (more complex restorations, endodontic treatment, confection of aesthetic devices, restraints).
Study NCT02053103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: Tablet, 200 mg, twice daily, 6 weeks
Study NCT02053103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, 0 mg, twice daily, 6 weeks
Study NCT01317641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201
Description: ODM-201 administered orally daily
Study NCT01631214 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Romosozumab 210 mg administered by subcutaneous injection once a month during the double-blind treatment phase.
Study NCT01631214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70 mg tablet taken once a week
Study NCT01631214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Alendronate 70 mg tablet taken once a week
Study NCT01631214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Romosozumab
Description: Administered by subcutaneous injection once a month during the double-blind treatment phase.
Study NCT01631214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Alendronate
Description: Matching placebo tablet taken once a week during the double-blind treatment phase.
Study NCT04518696 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suprachoroidal buckling
Description: Location, marking and freezing of the retinal tear on the scleral side . Subretinal fluid is released from the outside of the sclera as needed. In the quadrant of the retinal tear, the spherical conjunctiva was opened and the radial full-thickness scleral incision (3mm)was made about 8-13mm away from the retinal tear. After the choroid was exposed, a pocket is formed by injecting some viscoelastic agent into the posterior edge of the sclera and separating the choroid from the sclera using the Healon packaged cannula (No.27 Rycroft cannula). The Healon 5 syringe was connected with a 450-um special tube . The cannula is inserted into the supragromal space under microscopic and was scaned by iOCT . Once confirmed in accord with the needle position, sodium hyaluronate injection, usually need 0.2 mL to 0.5 mL, application of anterior chamber puncture or subretinal fluid stable intraocular pressure. Exit the duct and close the incision with scleral presutures.
Study NCT03994380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhDNAse Inhalation Solution
Description: rhDNAse 2.5 mg nebulizer daily for 4 weeks
Study NCT05601349 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth-based strategy
Description: Teleducation course, based on the CPG recommendations
Study NCT05601349 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telehealth-based strategy
Description: Teleducation course, based on the CPG recommendations
Study NCT04093271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rest-ZZZ
Description: A dietary supplement containing melatonin, valerian root, chamomile, passion flower, GABA, hawthorn berry, and lemon balm
Study NCT04093271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator - Diphenhydramine HCl
Description: DIN 02229960 encapsulated for blinding purposes
Study NCT04093271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No active ingredients
Study NCT01356095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knowledge translation intervention
Description: Two part intervention includes an educational outreach intervention for health care workers and a point of care patient education/counselling tool, delivered to providers within health centers randomized to the intervention arm, using a train the trainer on-site training model.
Study NCT01356095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palm-Plus
Description: Clinical guideline and training approach, designed for mid-level healthworkers.
Study NCT00048152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: As prescribed
Study NCT00048152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoral
Description: Low dose (target trough level 50-100ng/mL)
Study NCT00048152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoral
Description: Standard dose (target trough level 150-300ng/mL)
Study NCT00048152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zenapax
Description: 2mg/kg iv first dose, then 1mg/kg every 2 weeks
Study NCT00048152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: 1g po bid
Study NCT02189668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics only (Zosyn then Augmentin)
Description: Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic
Study NCT02303665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The dual therapy
Description: TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
Study NCT02303665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The triple therapy
Description: TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
Study NCT02392780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Oral cannabidiol at a dose of 150 mg BID up to 90 days.
Study NCT02392780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: IV methylprednisolone 2 mg/kg/day
Study NCT02392780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitor
Description: cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)
Study NCT02092753 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard diet (SD)
Description: Nutrition intervention following the recommendations of the germans society for nutrition (DGE)
Study NCT02092753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 1: Ketogenic diet (KD).
Description: Nutritional intervention: recommendations to follow a ketogenic diet
Study NCT02092753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 2: Low glycämic and insulinemic diet (LOGI)
Description: Nutritional intervention: patients were instructed to follow the LOGI diet regimen
Study NCT01075048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: ARQ 197 is supplied as a 120-mg capsule, administered twice daily at the dose determined in the Phase 1 portion of the study. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Study NCT01075048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ARQ 197, administered twice daily. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Study NCT01075048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 500 mg/ m\^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Study NCT01075048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 500 mg/ m\^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Study NCT01075048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 60 minutes after cetuximab, Irinotecan 180 mg/m\^2 intravenous infusion over 30 - 90 minutes. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Study NCT01075048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan
Description: 60 minutes after cetuximab, Irinotecan 180 mg/m\^2 intravenous infusion over 30 - 90 minutes. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Study NCT02433769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOFscan
Description: Data from the TOFscan will be compared to simultaneously measured data from the TOF-Watch-SX (gold standard)
Study NCT02433769 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOF-Watch-SX
Description: Data from the TOF-Watch-SX will be compared to simultaneously measured data from the TOFscan
Study NCT01364155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIM-0705
Study NCT01364155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study NCT04510272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aloud Real-time Reading of ICU Diaries
Description: Standard ICU diaries will be read aloud in real time daily to patients by ICU nurses/therapists/family members
Study NCT00104052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (PEG2b) (SCH 54031)
Description: PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) for 48 weeks.
Study NCT00104052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (SCH 18908)
Description: 15 mg/kg/day for up to 48 weeks
Study NCT01195649 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients under daily life treatment according to local drug information
Study NCT06609993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue ephedrine administration
Description: ephedrine (Ephedrinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 10 mg will be administered intravenously when DAP \< 50 mmHg or MAP \< 65 mmHg
Study NCT04212429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Ophthalmic Product
Description: Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
Study NCT04212429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Ophthalmic Solution
Description: Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
Study NCT01433159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP011-101 (Xenaderm Ointment)
Description: The test article will be applied at approximately the thickness of a dime twice daily, or more often if removed incidental to cleansing for 14 days treatment with HP011 101.
Study NCT01433159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin).
Study NCT04161391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPX-0046
Description: Oral TPX-0046 capsules
Study NCT00618293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haemate HS
Description: intravenous infusion of Haemate (dosage dependent on body weight)
Study NCT00618293 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl-solution
Description: intravenous infusion of 0.9%NaCl-Solution
Study NCT03659344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl plus
Description: Using vicryl sutures which coated with triclosan (antibiotic)
Study NCT00997334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT01287936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB623
Description: SB623, a modified stem-cell product
Study NCT04208893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: See description of Arms
Study NCT02402400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sub Lingual Ticagrelor
Description: 180mg sub-lingual ticagrelor
Study NCT02402400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sub Lingual Ticagrelor
Description: 180mg sub-lingual ticagrelor
Study NCT03713463 — intervention group
Intervention type: OTHER
Intervention: Oral Nutritional Supplement (ONS)
Description: Per standard of care (SOC)
Study NCT03316846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Delivered Cognitive Behavioral Therapy
Study NCT00785083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Study NCT00785083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03746496 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: point-of-care laboratory analysis
Description: POC analysis with i-STAT POC analyser from the intraosseous and arterial blood
Study NCT00947206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LHWO about CRC
Description: 2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt
Study NCT00947206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education + CRC brochure
Description: Bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
Study NCT00560963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT02047578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
Study NCT03037632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Heart Talk Booklet
Study NCT00266708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: risedronate 35 mg weekly
Study NCT00266708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Risedronate Placebo 35 mg weekly
Study NCT00419705 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NeuroThera® Laser System
Description: Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp